Researchers have developed a novel way to treat bladder cancer. Powered by urea, a waste substance found in urine, nanobots propel themselves to and penetrate the tumor to deliver their onboard ...

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first ...

From a biomarker-driven strategy to delay or avoid cystectomy, to practice-changing perioperative immunotherapy, developments ...

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...

When the treatment works, the 15-year survival rate for patients with so-called "non-muscle-invasive" (early-stage) bladder ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. When urologic oncologist Dan Theodorescu thinks about his 25 years ...

However, these therapies, which ramp up the production and activation of tumor cell-killing immune cells called T-cells, have not been effective in aggressive forms of prostate and bladder cancers.

Patients with tumors in the trigone and urethra were more likely to experience recurrence and cancer-specific death after radical cystectomy than patients with tumor only in the bladder walls.

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan. Urologic cancer care is shifting towards a less invasive, ...